Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer.

Therapeutic advances in medical oncology（2023）

引用 0|浏览10

暂无评分

摘要

This study indicated that compared with nab-paclitaxel monotherapy, combined nab-paclitaxel and ICIs failed to improve survival in relapsed SCLC.

查看译文

关键词

anti-PD-1, anti-PD-L1, chemotherapy, combination immunotherapy, small-cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要